Valuation : Monopar Therapeutics Inc.

Market Cap 76Cr 66Cr 61Cr 56Cr 106.02Cr 7.3TCr 106.32Cr 727.8Cr 284.51Cr 3.68TCr 287.14Cr 280.94Cr 12TCr P/E 2026 *
-45.6x
P/E 2027 * -45.5x
Enterprise Value 65Cr 55Cr 52Cr 48Cr 90Cr 6.17TCr 90Cr 614.78Cr 240.33Cr 3.11TCr 242.55Cr 237.31Cr 10TCr EV / Sales 2026 *
-
EV / Sales 2027 * 21.9x
Free-Float
76.63%
Yield 2026 *
-
Yield 2027 * -
1 day+0.19%
1 week+2.76%
Current month+5.16%
1 month+3.27%
3 months+76.51%
6 months+107.90%
Current year+74.49%
1 week 104.48
Extreme 104.48
117.5
1 month 104.48
Extreme 104.48
124.82
Current year 50.07
Extreme 50.07
124.82
1 year 32.77
Extreme 32.77
124.82
3 years 1.37
Extreme 1.3695
124.82
5 years 1.37
Extreme 1.3695
124.82
10 years 1.37
Extreme 1.3695
240
Manager TitleAgeSince
Chief Executive Officer 42 01/12/2014
Director of Finance/CFO 54 03/03/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 42 01/12/2014
Chairman 73 01/12/2014
Director/Board Member 84 01/04/2017
Date Insider Type Main position Quantity % Market Cap.
30/06/26 Fiscal year

Chief Financial Officer

2,963 0.0442%
30/06/26 Fiscal year

Chief Operating Officer

12,817 0.1913%
30/06/26 Fiscal year

Founder

29,830 0.4453%
Change 5-day change 1-year change 3-year change Capi.($)
+0.19%+2.76%+227.32%+3,352.73% 76Cr
-0.37%-0.95%+2.98%+23.36% 5.11TCr
+2.65%+4.45%+481.36%+567.32% 4.74TCr
+0.33%+2.47%+38.97%+19.80% 4.32TCr
-0.88%+0.90%+24.11%+87.74% 4.24TCr
-2.27%-3.02%+14.22%+51.50% 3.32TCr
-1.21%-0.17%+29.16%+135.38% 1.71TCr
-0.36%-2.14% - - 1.64TCr
-0.47%-0.22%+12.09%+28.32% 1.48TCr
+0.44%+1.70%+82.07%+47.92% 1.42TCr
Average -0.40%+0.84%+101.37%+479.34% 2.8TCr
Weighted average by Cap. -0.42%+1.05%+106.63%+152.77%

Financials

2026 *2027 *
Net sales - 2.83Cr 2.43Cr 2.27Cr 2.08Cr 3.92Cr 269.9Cr 3.93Cr 27Cr 11Cr 136.03Cr 11Cr 10Cr 450.19Cr
Net income -2.15Cr -1.84Cr -1.72Cr -1.58Cr -2.98Cr -204.99Cr -2.98Cr -20Cr -7.98Cr -103.32Cr -8.06Cr -7.88Cr -341.93Cr -2.66Cr -2.28Cr -2.14Cr -1.96Cr -3.69Cr -254.21Cr -3.7Cr -25Cr -9.9Cr -128.12Cr -9.99Cr -9.78Cr -424.03Cr
Net Debt -12Cr -10Cr -9.54Cr -8.74Cr -16Cr -1.13TCr -17Cr -113.02Cr -44Cr -571.65Cr -45Cr -44Cr -1.89TCr -14Cr -12Cr -12Cr -11Cr -20Cr -1.38TCr -20Cr -137.57Cr -54Cr -695.85Cr -54Cr -53Cr -2.3TCr
Logo Monopar Therapeutics Inc.
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Employees
-
Date Price Change Volume
27/26/27 $113.94 +0.19% 1,42,827
26/26/26 $113.72 +2.62% 1,23,770
25/26/25 $110.82 -0.48% 1,33,188
24/26/24 $111.36 +3.38% 2,39,187
21/26/21 $107.72 -2.85% 1,76,420
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
113.94USD
Average target price
126.31USD
Spread / Average Target
+10.85%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MNPR Stock